Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (Nasdaq: SRTS) has acquired two mobile aesthetic laser companies, Aesthetic Mobile Laser Services and Aesthetic Laser Partners, significantly expanding its dermatology customer base in Florida. These acquisitions are anticipated to generate an additional $1.0 million in revenue over the next 12 months and are immediately accretive to earnings. The new division, Sensus Laser Aesthetic Solutions, will be led by management from the acquired companies, enhancing market reach and technology integration as Sensus plans to introduce its own aesthetic laser products.
Sensus Healthcare (Nasdaq: SRTS) will hold a conference call on August 6, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and provide a business update, including recent and upcoming milestones. Investors can access the call via dial-in numbers or a live webcast. The company specializes in non-invasive treatments for oncological and non-oncological conditions, highlighting its innovative products like the Sculptura™ system and SRT-100™ series, aimed at improving patient quality of life.
Sensus Healthcare (Nasdaq: SRTS) has announced the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales, focusing on the Southeast Asian market for Superficial Radiation Therapy (SRT) products. Mr. Suen's experience includes nearly 20 years in medical device sales in Asia, contributing to the successful shipment of an SRT-100 system to China. CEO Joe Sardano expressed confidence in Mr. Suen's abilities, highlighting potential growth in shipments of SRT-100 units. Sensus specializes in non-invasive treatment devices targeting oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar on July 16, 2020. This event aims to discuss the reopening of medical practices post-COVID-19, exploring revenue recovery, patient engagement, and the adaptation of commercialization strategies. It will include Q&A sessions and panel discussions to share insights and strategies on navigating the changing healthcare landscape. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will participate in a panel discussion at the Fall Clinical Virtual Grand Rounds on June 30, 2020. The session is titled Directions in Dermatology and Their Impact on You: Patients, Practice and Pharma and focuses on superficial radiation therapy (SRT). This is part of a series aimed at providing continuing medical education (CME) to dermatologists during the pandemic. The event highlights Sensus’ commitment to supporting dermatology practices.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced that Dr. Jeffrey S. Fromowitz will discuss superficial radiation therapy at the Fall Clinical Virtual Grand Rounds today. This presentation will cover treatment for non-melanoma skin cancers and keloids, contributing to continuing medical education (CME) credits for participants. Dr. Fromowitz, a board-certified dermatologist, is affiliated with Dermatology of Boca and has advanced training in Mohs micrographic surgery. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) is hosting a program titled "Medical-Legal Issues in the Era of COVID-19" on June 18 at 3:00 p.m. ET. This event is part of a series aimed at discussing the role of superficial radiation therapy (SRT) amidst the pandemic. Hosted by CEO Joe Sardano and Dr. David Goldberg, the session addresses malpractice protections, employment issues, and telemedicine applications for SRT patients. The successful response to earlier events indicates strong interest in these discussions.
Sensus Healthcare (SRTS) reported Q1 2020 revenues of $1.7 million, down from $5.4 million in Q1 2019, attributed to COVID-19 impacts. The net loss widened to $3.6 million ($0.22 per share) from a loss of $2.1 million ($0.13 per share) a year prior. The company's installed base of SRT systems increased to 474, with four units shipped. Cash reserves rose slightly to $15.8 million. Management emphasized efforts to support customers during the pandemic and anticipates a potential increase in SRT adoption as reimbursement rates are expected to change in 2021.